BrainStorm Cell Therapeutics Transitioning to OTCQB After Nasdaq Delisting
BrainStorm Cell Therapeutics Moves to OTCQB Following Nasdaq Delisting
BrainStorm Cell Therapeutics Inc. BCLI has recently received a notification regarding the delisting of its common stock from the Nasdaq Capital Market. The company will experience this change starting at the open of trading, and the decision is attributed to non-compliance with Nasdaq Listing Rule 5550(b)(1), which pertains to minimum shareholder equity requirements.
Transition Plans to OTCQB Initiative
Despite the challenges posed by the delisting, BrainStorm has proactively secured approval to have its stock traded on the OTCQB Venture Market, which is operated by OTC Markets Group. It's expected that shares will commence trading under the same symbol, BCLI, shortly after the transition.
Addressing Shareholders and the Community
In light of these developments, Chaim Lebovits, CEO of BrainStorm Cell Therapeutics, emphasized the company's unwavering commitment to its core mission. He assured shareholders and the broader patient community that upcoming changes would not affect their dedication to advancing NurOwn, their investigational therapy aimed at treating ALS (amyotrophic lateral sclerosis).
Impact on Business Operations
BrainStorm clarified that this delisting will not impede its ongoing business operations or research and development initiatives. The company's focus remains steadfast on the development of its therapies, particularly NurOwn. Updates regarding business progress and adherence to SEC regulations will continue to be communicated.
The Promise of NurOwn Technology
BrainStorm's NurOwn technology platform represents a significant advancement in therapeutic approaches targeting neurodegenerative disorders. The investigational therapies utilize autologous mesenchymal stem cells (MSCs), which are developed into neurotrophic factor-secreting cells, known as MSC-NTF cells. These cells play a vital role in delivering therapeutic treatment directly to the neurodegeneration sites, contributing to disease management.
Research and Development Endeavors
Currently, NurOwn is the leading investigational therapy for ALS, having received Orphan Drug designation from both U.S. and European regulatory agencies. BrainStorm has successfully completed a pivotal Phase 3 trial and is preparing to launch a Phase 3b trial under a Special Protocol Assessment with the FDA to enhance treatment accessibility for ALS patients.
Expanding Research Horizons
In addition to their efforts in ALS, BrainStorm has also made significant strides in the realm of multiple sclerosis (MS). A Phase 2 open-label multicenter trial has been successfully concluded, adding to the growing body of research supporting the efficacy of MSC-NTF cells. Further innovations include the development of an allogeneic exosome-based platform, designed to deliver therapeutic proteins effectively, which adds another dimension to their therapeutic approach.
Future Prospects and Innovations
The recent notice regarding the transition to OTCQB is a stepping stone rather than a setback for BrainStorm. The company’s commitment to advancing its innovative treatments for debilitating conditions continues to inspire confidence among stakeholders. The continued exploration into regenerative medicine and the advancement of their unique technologies positions BrainStorm at the forefront of therapeutic innovation.
Frequently Asked Questions
What prompted BrainStorm Cell Therapeutics' delisting from Nasdaq?
The delisting was due to non-compliance with Nasdaq’s minimum shareholder equity requirements under Rule 5550(b)(1).
Where will BrainStorm's shares be traded following the delisting?
Shares of BrainStorm will transition to trading on the OTCQB Venture Market, retaining the ticker symbol BCLI.
How does this transition affect the company's operations?
The delisting will not impact BrainStorm's ongoing business operations or research initiatives focused on ALS treatments.
What is the NurOwn technology platform?
NurOwn is an investigational platform that utilizes MSCs to create cells that secrete neurotrophic factors, aimed at treating neurodegenerative diseases.
What trials is BrainStorm currently engaged in?
BrainStorm is preparing for a Phase 3b trial of NurOwn under a Special Protocol Assessment with the FDA, along with ongoing studies in multiple sclerosis.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
